Moderna, Inc. Common Stock
MRNAModerna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) technology to develop vaccines and therapeutics. Founded in 2010, it gained prominence with its COVID-19 vaccine, playing a key role in the global response to the pandemic. Moderna focuses on innovative mRNA solutions for infectious diseases, cancer, rare diseases, and other conditions.
Company News
ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as...
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its dominant cystic fibrosis portfolio into rare endocrine disorders. The deal provides access to Palsonify for acromegaly and a pipeline asset for congenital adrenal hyperplasia, potentially adding $5 billion in peak annual revenue. While the...
Moderna's stock has more than doubled this year as the company transitions from a COVID-19 vaccine maker to a diversified biotech firm. With multiple late-stage vaccine programs (flu, norovirus, combination vaccines) and cancer therapies in development, the company is preparing for major product launches in 2027-2028. Strong financials including ...
Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb ano...
The Fidelity MSCI Health Care Index ETF (FHLC) offers broad healthcare sector exposure with lower costs (0.08% expense ratio), higher dividend yield (1.3%), and lower volatility, making it suitable for conservative investors. The State Street SPDR S&P Biotech ETF (XBI) focuses on biotechnology with higher growth potential (89.3% 1-year return) bu...
